Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy.

With Fund II, which closed at $300 million on Thursday, Biomatics’ Julie Sunderland said, “we’ve gotten more nuanced and will focus on three specific areas,” including therapeutics and diagnostics, enabling R&D technologies and data-driven clinical practice tools. The VC closed its first fund at $200 million last year to invest in genomics and digital health companies (see “Personal Stakes”)...